Results 171 to 180 of about 152,178 (350)

Optimizing the integration of modern systemic therapies and advanced radiotherapy techniques in breast cancer management: An expert opinion from the Institut Curie Breast Radiotherapy Group

International Journal of Cancer, Volume 158, Issue 7, Page 1775-1784, 1 April 2026.
Abstract The integration of modern systemic therapies with radiotherapy (RT) represents a promising strategy in breast cancer management, enhancing both locoregional control and systemic disease outcomes. This expert consensus from the Institut Curie Breast Radiotherapy Group focuses exclusively on modern systemic agents, synthesizing current evidence ...
Cezara Cheptea, Pierre Loap, Sofiane Allali, Alain Fourquet, Kim Cao, Youlia Kirova   +5 more
wiley   +1 more source

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.

New England Journal of Medicine, 2005
E. Romond, E. Perez, J. Bryant, V. Suman, C. Geyer, N. Davidson, E. Tan-chiu, S. Martino, S. Paik, P. Kaufman, S. Swain, T. Pisansky, L. Fehrenbacher, L. Kutteh, V. Vogel, D. Visscher, G. Yothers, R. Jenkins, Ann M. Brown, S. Dakhil, E. Mamounas, W. Lingle, P. Klein, J. Ingle, N. Wolmark   +24 more
semanticscholar   +1 more source

Delivering precision oncology in metastatic breast cancer: Clinical impact of comprehensive genomic profiling—The CATCH experience

International Journal of Cancer, Volume 158, Issue 6, Page 1675-1689, 15 March 2026.
What's new? CATCH is a prospective precision oncology registry trial that harnesses whole‐genome/exome‐ and RNA‐sequencing to enable actionable biomarker detection in metastatic breast cancer patients of any subtype. The data of the first 412 consecutive patients with completed follow‐up in this real‐world, single‐center patient cohort provide robust ...
Mario Hlevnjak, Sabine Heublein, Verena Thewes, Lukas Wagener, Constantin Pixberg, Carlo Fremd, Laura Michel, Christian Maurer, Lars Buschhorn, Nicola Dikow, Fangyoumin Feng, Stefan Fröhling, Christel Herold‐Mende, Steffen Hirsch, Chen Hong, Daniel Hübschmann, Lena Jassowicz, Polina Kozyulina, Katrin Pfütze, Richard F. Schlenk, Hans‐Peter Sinn, Katharina Smetanay, Christoph Springfeld, Albrecht Stenzinger, Celina Wagner, Stephan Wolf, Andreas Trumpp, Dirk Jäger, Oliver Zivanovic, Marc Zapatka, Andreas Schneeweiss, Peter Lichter   +31 more
wiley   +1 more source

PCN167 INFORMING THE DECISION: IMPROVING GENERALIZABILITY BY PARAMETERIZING RELEVANT INFORMATION IN THE ECONOMIC EVALUATION OF TRASTUZUMAB IN EARLY BREAST CANCER

, 2010
MA Joore, Ties Hoomans, Vivianne C. G. Tjan‐Heijnen, SC Seferina, WG Goettsch, Jan C. Grutters   +5 more
openalex   +1 more source

A phase II trial of dasatinib (D) in combination with trastuzumab (T) and paclitaxel (P) in the first line treatment of HER2 positive metastatic breast cancer (MBC) patients (pts): GEICAM/2010-04 [PDF]

, 2017
A. Ocana Fernandez, Manuel Ruíz Borrego, Marta Gil-Martín, Silvia Antolín, M. Atienza, Alfredo Montaño, Nuria Ribelles, A. Guerrero, Montserrat Muñoz-Mateu, I. Fernández-Pérez, Ander Urruticoechea, Alejandro Falcón, Sònia Pernas, J. Prato Varela, M.J. Escudero, Sara Benito, Rosalía Caballero, Eva Carrasco, Federico Rojo, Atanasio Pandiella   +19 more
openalex   +1 more source

Tamoxifen/Trastuzumab Regimen [PDF]

, 2020
National Cancer Institute
openalex   +1 more source

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

New England Journal of Medicine, 2005
M. Piccart-Gebhart, M. Procter, B. Leyland-Jones, A. Goldhirsch, M. Untch, I. Smith, L. Gianni, J. Baselga, R. Bell, C. Jackisch, D. Cameron, M. Dowsett, C. Barrios, G. Steger, C. Huang, M. Andersson, M. Inbar, M. Lichinitser, I. Láng, U. Nitz, H. Iwata, C. Thomssen, C. Lohrisch, T. Suter, J. Rüschoff, T. Suto, V. Greatorex, C. Ward, C. Straehle, E. McFadden, M. Dolci, R. Gelber   +31 more
semanticscholar   +1 more source

Addressing Causality and Homogeneity Assumptions in Exposure‐Response Analyses

Clinical Pharmacology &Therapeutics, Volume 119, Issue 3, Page 703-712, March 2026.
Exposure‐response, or pharmacokinetic–pharmacodynamic (PKPD), analyses support many drug development decisions. It is typically applied without assessment of causality and homogeneity, where the latter refers to the assumption that the reason for variability in exposure is unimportant for the impact on response.
Mats O. Karlsson, Divya Brundavanam
wiley   +1 more source

Trastuzumab Emtansine (T-DM1) in Patients (pts) With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC): results From a Multicenter Retrospective Analysis [PDF]

, 2016
Laura Pizzuti, Isabella Sperduti, Andrea Michelotti, Claudia Omarini, Teresa Gamucci, Clara Natoli, Loretta D’Onofrio, Francesco Giotta, Corrado Ficorella, Lucio Laudadio, Alessandra Cassano, Paolo Marchetti, Vincenzo Adamo, M. Mauri, A.F. Scinto, G. Zampa, Agnese Fabbri, Lucia Mentuccia, Sandro Barni, Patrizia Vici   +19 more
openalex   +1 more source

Trastuzumab emtansine for HER2-positive advanced breast cancer.

New England Journal of Medicine, 2012
S. Verma, D. Miles, L. Gianni, I. Krop, M. Welslau, J. Baselga, M. Pegram, D. Oh, V. Diéras, E. Guardino, L. Fang, Michael W. Lu, S. Olsen, K. Blackwell   +13 more
semanticscholar   +1 more source